Durata's Dalvance aims to shift ABSSSI treatment; priority review granted
This article was originally published in Scrip
Executive Summary
Shares of Durata Therapeutics jumped 8.4% in after-hours trading on 26 November on word the FDA granted a priority review to the company's new drug application (NDA) for Dalvance (dalbavancin) as a treatment for patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive microorganisms, including methicillin resistant Staphylococcus aureus (MRSA).